Meanwhile, in the retrospective study which included patients with stage IV EGFR-mutant NSCLC who had oligometastatic disease during first-line EGFR-TKI therapy, Xu et al. implied that only LCT to all sites can prolong PFS [16]. Here, EGFR is linked to non-small cell lung carcinoma.